ASH/FDA update on von Willebrand factor (Recombinant)
This webinar recording discusses the FDA approval of von Willebrand factor (Recombinant), for use in adults 18 years of age and older who have von Willebrand disease (VWD). This is the first FDA-approved recombinant von Willebrand factor for the on-demand (as needed) treatment and control of bleeding episodes in adults diagnosed with VWD.
Paula James, MD, FRCPC, Professor, Department of Medicine, Queen's University, Kingston, Ontario
Victor Baum, MD, Division of Hematology Clinical Review, U.S. Food and Drug Administration, Silver Spring, MD; Adjunct Professor of Anesthesiology & Pediatrics, George Washington Univ. School of Medicine
Margaret V. Ragni, MD, MPH, Professor of Medicine and Clinical Translational Science, University of Pittsburgh Medical Center, Director, Hemophilia Center of Western PA, Pittsburgh, PA